Mustafa Umut Somuncu1, Ali Riza Demir2, Seda Tukenmez Karakurt2, Huseyin Karakurt2, Turgut Karabag3. 1. Bulent Ecevit University - Faculty of Medicine -, Department of Cardiology, Zonguldak - Turkey. 2. Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul - Turkey. 3. Istanbul University, Istanbul - Turkey.
Abstract
BACKGROUND: A subset of patients who take antiplatelet therapy continues to have recurrent cardiovascular events which may be due to antiplatelet resistance. The effect of low response to aspirin or clopidogrel on prognosis was examined in different patient populations. OBJECTIVE: We aimed to investigate the prevalence of poor response to dual antiplatelet therapy and its relationship with major adverse cardiovascular events (MACE) in young patients with ST-elevation myocardial infarction (STEMI). METHODS: In our study, we included 123 patients under the age of 45 with STEMI who underwent primary percutaneous intervention. A screening procedure to determine both aspirin and clopidogrel responsiveness was performed on the fifth day of admission. We followed a 2x2 factorial design and patients were allocated to one of four groups, according to the presence of aspirin and/or clopidogrel resistance. Patients were followed for a three-year period. A p-value less than 0.05 was considered statistically significant. RESULTS: We identified 48% of resistance against one or more antiplatelet in young patients with STEMI. More MACE was observed in patients with poor response to dual platelet therapy or to clopidogrel compared those with adequate response to the dual therapy (OR: 1.875, 1.144-3.073, p < 0.001; OR: 1.198, 0.957-1.499, p = 0.036, respectively). After adjustment for potential confounders, we found that poor responders to dual therapy had 3.3 times increased odds for three-year MACE than those with adequate response to the dual therapy. CONCLUSION: Attention should be paid to dual antiplatelet therapy in terms of increased risk for cardiovascular adverse events especially in young patients with STEMI.
BACKGROUND: A subset of patients who take antiplatelet therapy continues to have recurrent cardiovascular events which may be due to antiplatelet resistance. The effect of low response to aspirin or clopidogrel on prognosis was examined in different patient populations. OBJECTIVE: We aimed to investigate the prevalence of poor response to dual antiplatelet therapy and its relationship with major adverse cardiovascular events (MACE) in young patients with ST-elevation myocardial infarction (STEMI). METHODS: In our study, we included 123 patients under the age of 45 with STEMI who underwent primary percutaneous intervention. A screening procedure to determine both aspirin and clopidogrel responsiveness was performed on the fifth day of admission. We followed a 2x2 factorial design and patients were allocated to one of four groups, according to the presence of aspirin and/or clopidogrel resistance. Patients were followed for a three-year period. A p-value less than 0.05 was considered statistically significant. RESULTS: We identified 48% of resistance against one or more antiplatelet in young patients with STEMI. More MACE was observed in patients with poor response to dual platelet therapy or to clopidogrel compared those with adequate response to the dual therapy (OR: 1.875, 1.144-3.073, p < 0.001; OR: 1.198, 0.957-1.499, p = 0.036, respectively). After adjustment for potential confounders, we found that poor responders to dual therapy had 3.3 times increased odds for three-year MACE than those with adequate response to the dual therapy. CONCLUSION: Attention should be paid to dual antiplatelet therapy in terms of increased risk for cardiovascular adverse events especially in young patients with STEMI.
Authors: J M Siller-Matula; G Delle-Karth; I M Lang; T Neunteufl; M Kozinski; J Kubica; G Maurer; K Linkowska; T Grzybowski; K Huber; B Jilma Journal: J Thromb Haemost Date: 2012-04 Impact factor: 5.824
Authors: P P Wisman; M Roest; F W Asselbergs; P G de Groot; F L Moll; Y van der Graaf; G J de Borst Journal: J Thromb Haemost Date: 2014-05 Impact factor: 5.824
Authors: Tina L Pinto Slottow; Laurent Bonello; Rekha Gavini; Patricia Beauzile; Steven J Sushinsky; Mickey Scheinowitz; Kimberly Kaneshige; Zhenyi Xue; Rebecca Torguson; Udaya Tantry; Augusto D Pichard; Lowell F Satler; William O Suddath; Kenneth Kent; Paul Gurbel; Ron Waksman Journal: Am J Cardiol Date: 2009-06-24 Impact factor: 2.778
Authors: Jaapjan D Snoep; Marcel M C Hovens; Jeroen C J Eikenboom; Johanna G van der Bom; Menno V Huisman Journal: Arch Intern Med Date: 2007 Aug 13-27
Authors: Stefanos G Foussas; Michael N Zairis; Vasilios G Tsirimpis; Stamatis S Makrygiannis; Nikolaos G Patsourakos; Evdokia N Adamopoulou; Demetrios Z Mytas; Athanasios A Prekates; Anna J Perdiou; Vasilios K Tsoukanas; Spyros K Argyrakis Journal: Clin Cardiol Date: 2009-03 Impact factor: 2.882